Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Dermacyd PH_DETINBACK (Lactic Acid)
Dermacyd PH_DETINBACK · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Dermacyd PH\_DETINBACK (Lactic Acid) |
| Name | Type | Description |
|---|---|---|
| Dermacyd PH_DETINBACK (Lactic Acid) | DRUG | - |
Inclusion criteria: * Phototype Skin II and III; * Integral skin test in the region; * Willingness in following the study procedures and to be present in the clinic at the days and scheduled time for medical evaluations and for application of occlusion; Exclusion criteria: * Lactation or gestatio...
Dermacyd PH_DETINBACK is an investigational small molecule developed by Sanofi for hygiene use. It is also known as Dermacyd PH_DETINBACK (Lactic Acid). The product has been studied in Phase 3 clinical trials conducted in Brazil, with two completed trials that enrolled a total of 79 participants.
Dermacyd PH_DETINBACK is being developed for hygiene purposes. Its clinical trials have been conducted in the hygiene condition, specifically among healthy female volunteers aged 18 years and older in Brazil. The specific hygiene indication has not been publicly disclosed.
Dermacyd PH_DETINBACK is developed by Sanofi, which trades under the ticker SNY. Sanofi is the sponsor of the clinical trials evaluating this product.
Dermacyd PH_DETINBACK is in Phase 3 clinical development. Both of its Phase 3 trials have been completed, and there are currently no active trials. The program has not been approved by the FDA and remains investigational.
Dermacyd PH_DETINBACK has been evaluated in two completed Phase 3 trials: NCT00785720, titled Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower - Photo Avaluation, which enrolled 26 participants, and NCT00785681, titled Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower - Compatibility, which enrolled 53 participants. Both trials were conducted in Brazil.
Yes, Dermacyd PH_DETINBACK is also known as Dermacyd PH_DETINBACK (Lactic Acid). The parenthetical name reflects its lactic acid component. Both names refer to the same Sanofi investigational product studied in Phase 3 hygiene trials.